Searching...
10 results for “ai drug discovery”
...drug discovery, I mean, as you have alluded to, I think that the idea that we're going to be able to have kind of an end to end black box where you type in a patient profile and and disease and outcomes, the molecular design of a cure is purely scien
10:21 / 11:31
from transcript10:21 – 11:31
...drug discovery are are usually looking at, like, one, two, or three targets. But, again, it was important for us if we were seeing this as an engineering problem to make sure that this is gonna be generalizable. It's like imagine you had a new LLM pa
9:45 / 10:59
from transcript9:45 – 10:59
...AI drug discovery continues to increase, the number of drugs being produced will simply continue to increase. Creating novel drug molecules will almost, to some degree, become commodified. But what will become really critical then is actually trying
33:33 / 34:52
from transcript33:33 – 34:52
...discovery, you need to understand how multiple molecules interact with one another. So you need to understand how a small molecule drug is going to modulate a protein or how an antibody protein is going to modulate an an antigen protein. So we starte
0:40 / 2:45
from transcript0:40 – 2:45
...drug discovery are so, like, tightly interwoven, and, you know, that's that's really what we need these models to help accelerate.
39:05 / 40:10
from transcript39:05 – 40:10
...a drug and try, can we design them from, from the get go? The thing about those properties in some of them, you know, you need to, you know, start having an understanding of the cell. And so that's on the one end kind of why we need that understandin
1:14:14 / 1:15:19
from transcript1:14:14 – 1:15:19
...drugs is is this slow screening process. And this will allow us to kinda really leapfrog that that, that entire pipeline. Ninety percent of drugs fail in clinical trials. So, you know, we're pretty bad at making drugs. Right? And I think that implies
38:15 / 39:28
from transcript38:15 – 39:28
...are not drugs. You know, these are not things that are ready to be put into, into a human. And there is still a lot of development that, that goes with it. And so this is, this is kind of to, to us, you know, we see ourselves as, you know, building t
1:11:54 / 1:13:05
from transcript1:11:54 – 1:13:05
process that we've been talking about today. There's designing. There's the making. There's the testing. There's the approvals side of it. And, you know, I think the I I do think safety and efficacy as the kind of two pillars in the industry are the
41:15 / 42:25
from transcript41:15 – 42:25
...for discovery, but also because if in the case of success, it could be industrially really useful. Right? But, you know, we'll we'll we'll we'll have to see over time. Right? If we have ninety percent of drugs failing in clinical trials, right, that
23:12 / 24:25
from transcript23:12 – 24:25
Have a podcast?
Run your podcast through Clypt
Get ranked clips, hooks, and ready-to-post copy from your own episodes. Free to try.